Cytolytic Virus Activation Therapy for Epstein-Barr Virus―Driven Tumors

• Published in: Clinical cancer research Vol. 18; no. 18; pp. 5061 - 5070
• Main Authors: WILDEMAN, Maarten A, NOVALIC, Zlata, VERKUIJLEN, Sandra A. W. M, JUWANA, Hedy, HUITEMA, Alwin D. R, BING TAN, I, MIDDELDORP, Jaap M, DE BOER, Jan Paul, GREIJER, Astrid E
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15.09.2012
• Subjects: Antibodies, Viral - blood; Antibodies, Viral - immunology; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma; Cell Line, Tumor; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; DNA, Viral - genetics; Dose-Response Relationship, Drug; Epstein-Barr virus; Female; Herpesvirus 4, Human - drug effects; Herpesvirus 4, Human - immunology; Herpesvirus 4, Human - pathogenicity; Humans; Immunoglobulin G - blood; Immunoglobulin G - immunology; Infectious diseases; Male; Medical sciences; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms - drug therapy; Nasopharyngeal Neoplasms - pathology; Nasopharyngeal Neoplasms - virology; Neoplasm Staging; Pharmacology. Drug treatments; Treatment Outcome; Valproic Acid - administration & dosage; Viral diseases; Viral Load; Virus Activation - drug effects; Gammaherpesvirinae; Infection; Virus; Cytolysis; Regulation(control); Treatment; Herpesviridae; Viral disease; Activation; Epstein Barr virus; Malignant tumor; Cancer

Nasopharyngeal carcinoma (NPC) is causally linked to Epstein-Barr virus (EBV) infection. Because all tumor cells carry EBV, the virus itself is a potential target for therapy. In these tumor cells, EBV hides in a latent state and expresses only a few non-immunogenic proteins for EBV maintenance and...